

TABLE 3

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT  
SPECIFIC SITES IN MALE RATS TREATED WITH 1,5-NAPHTHALENEDIAMINE<sup>a</sup>

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Subcutaneous Tissue: Fibroma <sup>b</sup>	1/25(0.04)	3/49(0.06)	2/50(0.04)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.531	1.000
Lower Limit	---	0.133	0.056
Upper Limit	---	78.493	56.712
Weeks to First Observed Tumor	99	106	102
Skin: Squamous-Cell Papilloma <sup>b</sup>	2/25(0.08)	1/49(0.02)	1/50(0.02)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.255	0.250
Lower Limit	---	0.005	0.004
Upper Limit	---	4.707	4.616
Weeks to First Observed Tumor	109	106	106
Lung: Alveolar/Bronchiolar Adenoma or Alveolar/Bronchiolar Carcinoma <sup>b</sup>	0/25(0.00)	3/49(0.06)	4/47(0.09)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	Infinite	Infinite
Lower Limit	---	0.315	0.508
Upper Limit	---	Infinite	Infinite
Weeks to First Observed Tumor	---	104	106

TABLE 3 (CONTINUED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Hematopoietic System: Leukemia or Malignant Lymphoma <sup>b</sup>	1/25(0.04)	10/49(0.20)	10/50(0.20)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	5.107	5.000
Lower Limit	---	0.801	0.787
Upper Limit	---	212.137	213.351
Weeks to First Observed Tumor	109	100	97
Liver: Hepatocellular Carcinoma or Neoplastic Nodule <sup>b</sup>	1/25(0.04)	7/49(0.14)	4/49(0.08)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	3.571	2.041
Lower Limit	---	0.503	0.218
Upper Limit	---	156.046	96.949
Weeks to First Observed Tumor	109	106	104
Pituitary: Adenoma NOS, Chromophobe Adenoma, Acidophil Adenoma, or Basophil Adenoma <sup>b</sup>	2/22(0.09)	7/44(0.16)	11/44(0.25)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.750	2.750
Lower Limit	---	0.376	0.683
Upper Limit	---	16.365	24.081
Weeks to First Observed Tumor	98	96	65

TABLE 3 (CONTINUED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Adrenal: Pheochromocytoma or Malignant Pheochromocytoma <sup>b</sup>	2/24(0.08)	4/48(0.08)	5/48(0.10)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.000	1.250
Lower Limit	---	0.157	0.226
Upper Limit	---	10.563	12.529
Weeks to First Observed Tumor	109	106	102
Thyroid: C-Cell Carcinoma <sup>b</sup>	2/21(0.10)	3/47(0.06)	3/47(0.06)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.670	0.670
Lower Limit	---	0.084	0.084
Upper Limit	---	7.650	7.650
Weeks to First Observed Tumor	97	100	106
Thyroid: C-Cell Adenoma or C-Cell Carcinoma <sup>b</sup>	2/21(0.10)	5/47(0.11)	8/47(0.17)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.117	1.787
Lower Limit	---	0.205	0.405
Upper Limit	---	11.249	16.445
Weeks to First Observed Tumor	97	100	104

TABLE 3 (CONCLUDED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Pancreatic Islets: Islet-Cell Adenoma or Islet-Cell Carcinoma <sup>b</sup>	1/25(0.04)	2/48(0.04)	5/45(0.11)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.042	2.778
Lower Limit	---	0.058	0.340
Upper Limit	---	60.184	128.213
Weeks to First Observed Tumor	98	106	104
Testis: Interstitial-Cell Tumor <sup>b</sup>	21/25(0.84)	44/49(0.90)	45/49(0.92)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.069	1.093
Lower Limit	---	0.890	0.912
Upper Limit	---	1.325	1.324
Weeks to First Observed Tumor	97	94	65

<sup>a</sup>Treated groups received doses of 0.05 or 0.10 percent in feed.

<sup>b</sup>Number of tumor-bearing animals/number of animals examined at site (proportion).

<sup>c</sup>The probability level for the Cochran-Armitage test is given beneath the incidence of tumors in the control group when  $P < 0.05$ ; otherwise, not significant (N.S.) is indicated. The probability level for the Fisher exact test for the comparison of a treated group with the control group is given beneath the incidence of tumors in the treated group when  $P < 0.05$ ; otherwise, not significant (N.S.) is indicated. For both Cochran-Armitage and Fisher exact tests a negative designation (N) indicates a lower incidence in the treated group(s) than in the control group.

<sup>d</sup>The 95% confidence interval on the relative risk of the treated group to the control group.

TABLE 4 (CONTINUED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Thyroid: C-Cell Carcinoma <sup>b</sup>	1/21(0.05)	5/49(0.10)	1/48(0.02)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	2.143	0.438
Lower Limit	---	0.266	0.006
Upper Limit	---	99.147	33.659
Weeks to First Observed Tumor	109	106	106
Thyroid: C-Cell Adenoma or C-Cell Carcinoma <sup>b</sup>	1/21(0.05)	12/49(0.24)	4/48(0.08)
P Values <sup>c</sup>	N.S.	P = 0.046	N.S.
Departure from Linear Trend <sup>e</sup>	P = 0.009	---	---
Relative Risk (Control) <sup>d</sup>	---	5.143	1.750
Lower Limit	---	0.855	0.192
Upper Limit	---	215.370	83.548
Weeks to First Observed Tumor	109	104	103
Thyroid: Papillary Carcinoma, Follicular-Cell Carcinoma, or Papillary Cystadenocarcinoma NOS <sup>b</sup>	1/21(0.05)	1/49(0.02)	3/48(0.06)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.429	1.313
Lower Limit	---	0.006	0.115
Upper Limit	---	32.983	67.452
Weeks to First Observed Tumor	110	106	99

TABLE 4 (CONTINUED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Thyroid: Papillary Carcinoma, Follicular-Cell Carcinoma, Papillary Cystadenocarcinoma NOS, or Papillary Cystadenoma <sup>b</sup>	1/21(0.05)	2/49(0.04)	4/48(0.08)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.857	1.750
Lower Limit	---	0.648	0.191
Upper Limit	---	49.555	84.310
Weeks to First Observed Tumor	110	106	81
Mammary Gland: Fibroadenoma <sup>b</sup>	4/24(0.17)	5/50(0.10)	13/50(0.26)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.600	1.560
Lower Limit	---	0.145	0.556
Upper Limit	---	2.812	6.019
Weeks to First Observed Tumor	109	102	98
Mammary Gland: Fibroadenoma, Adenocarcinoma NOS, or Papillary Adenocarcinoma <sup>b</sup>	4/24(0.17)	5/50(0.10)	14/50(0.28)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.600	1.680
Lower Limit	---	0.145	0.609
Upper Limit	---	2.807	6.412
Weeks to First Observed Tumor	109	102	98

TABLE 4 (CONTINUED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Clitoral Gland: Carcinoma NOS <sup>b</sup>	1/24(0.04)	3/50(0.06)	8/50(0.16)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.440	3.840
Lower Limit	---	0.125	0.566
Upper Limit	---	75.487	168.221
Weeks to First Observed Tumor	110	106	69
Clitoral Gland: Adenoma NOS or Carcinoma NOS <sup>b</sup>	1/24(0.04)	3/50(0.06)	13/50(0.26)
P Values <sup>c</sup>	P = 0.003	N.S.	P = 0.021
Relative Risk (Control) <sup>d</sup>	---	1.440	6.240
Lower Limit	---	0.125	1.043
Upper Limit	---	74.077	258.268
Weeks to First Observed Tumor	110	106	69
Uterus: Endometrial Stromal Polyp <sup>b</sup>	2/24(0.08)	14/49(0.29)	20/48(0.42)
P Values <sup>c</sup>	P = 0.003	P = 0.043	P = 0.003
Relative Risk (Control) <sup>d</sup>	---	3.429	5.000
Lower Limit	---	0.892	1.385
Upper Limit	---	29.588	41.202
Weeks to First Observed Tumor	102	88	96

TABLE 4 (CONCLUDED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Uterus and Endometrium: Adenocarcinoma NOS <sup>b</sup>	1/24(0.04)	2/49(0.04)	4/48(0.08)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.980	2.000
Lower Limit	---	0.054	0.216
Upper Limit	---	56.627	96.367
Weeks to First Observed Tumor	110	104	106
Zymbal's Gland: Sebaceous Adenocarcinoma <sup>b</sup>	0/24(0.00)	0/50(0.00)	3/50(0.06)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	---	Infinite
Lower Limit	---	---	0.296
Upper Limit	---	---	Infinite
Weeks to First Observed Tumor	---	---	89

<sup>a</sup>Treated groups received doses of 0.05 or 0.10 percent in feed.

<sup>b</sup>Number of tumor-bearing animals/number of animals examined at site (proportion).

<sup>c</sup>The probability level for the Cochran-Armitage test is given beneath the incidence of tumors in the control group when  $P < 0.05$ ; otherwise, not significant (N.S.) is indicated. The probability level for the Fisher exact test for the comparison of a treated group with the control group is given beneath the incidence of tumors in the treated group when  $P < 0.05$ ; otherwise, not significant (N.S.) is indicated. For both Cochran-Armitage and Fisher exact tests a negative designation (N) indicates a lower incidence in the treated group(s) than in the control group.

<sup>d</sup>The 95% confidence interval on the relative risk of the treated group to the control group.

<sup>e</sup>The probability level of the test for departure from linear trend is given beneath the control group when  $P < 0.05$ .



every type of tumor in either sex where at least two such tumors were observed in at least one of the control or 1,5-naphthalenediamine-dosed groups and where such tumors were observed in at least 5 percent of the group.

For female rats an increased incidence of endometrial stromal polyps was observed in both the high and low dose groups compared to the control group. The Cochran-Armitage test indicated a significant ( $P = 0.003$ ) positive association between compound administration and tumor incidence. The Fisher exact tests supported this result with a significant ( $P = 0.003$ ) comparison of the high dose group to the control; for the low dose comparison the probability level was  $P = 0.043$ , a marginal result which was not significant under the Bonferroni criterion. Based on these results, the administration of 1,5-naphthalenediamine was associated with an elevated incidence of endometrial stromal polyps in female rats.

A number of adenomas NOS and carcinomas NOS of the clitoral gland were observed in female rats. The Cochran-Armitage test indicated a significant ( $P = 0.003$ ) positive association between dose and the combined incidence of adenomas NOS or carcinomas NOS of the clitoral gland. The Fisher exact test comparing high dose to control was also significant ( $P = 0.021$ ). In historical data collected by this laboratory for the NCI Carcinogenesis Testing Program, 4/249 (2 percent) of the untreated female Fischer 344 rats had one of these tumors, compared to the 13/50 (26 percent) observed in the high dose group in

this bioassay. Based upon these statistical results, the administration of 1,5-naphthalenediamine was associated with an elevated incidence of clitoral gland neoplasms in female rats.

For females the Fisher exact test comparing control to low dose for the combined incidence of C-cell adenomas or C-cell carcinomas of the thyroid had a probability level of  $P = 0.046$ , a marginal result which was not significant under the Bonferroni criterion.

Based on these statistical tests, it is concluded that 1,5-naphthalenediamine was carcinogenic for female rats, producing tumors of the clitoral gland and uterus.

#### IV. CHRONIC TESTING RESULTS: MICE

##### A. Body Weights and Clinical Observations

Mean body weight depression was readily apparent in dosed male mice when compared to controls. A similar but less pronounced trend was evident in dosed females (Figure 4).

One low dose male had a soft subcutaneous mass on the leg and two males in this group had palpable abdominal masses. Firm nodular growths developed in one low dose male and two high dose females. Alopecia was observed in 27 control males, 16 low dose males, 4 high dose males, 25 control females, and 3 low dose females. Two low dose and two high dose males experienced noticeable swelling of the eyes. Abdominal distention was observed in one control male and one control female mouse.

##### B. Survival

The estimated probabilities of survival for male and female mice in the control and 1,5-naphthalenediamine-dosed groups are shown in Figure 5. There was no significant positive association between dosage and mortality for either male or female mice.

Adequate numbers of male mice were at risk from late-developing tumors with 58 percent (29/50) of the high dose, 78 percent (39/50) of the low dose and 66 percent (33/50) of the controls surviving on test until the termination of the study. The 6 control male mice that died in week 11 were autolyzed, as were 2 of the 4 high dose male mice that died in week 41.







FIGURE 4  
GROWTH CURVES FOR 1,5-NAPHTHALENE-DIAMINE CHRONIC STUDY MICE



**FIGURE 5**  
**SURVIVAL COMPARISONS OF 1,5-NAPHTHALENEDIAMINE CHRONIC STUDY MICE**

For female mice, with 68 percent (34/50) of the high dose, 82 percent (41/50) of the low dose and 60 percent (30/50) of the control mice surviving on test until the termination of the study, adequate numbers were at risk from late-developing tumors.

C. Pathology

Histopathologic findings on neoplasms in mice are summarized in Appendix B (Tables B1 and B2); findings on nonneoplastic lesions are summarized in Appendix D (Tables D1 and D2).

Dietary administration of 1,5-naphthalenediamine produced an increase in hepatocellular neoplasms in female mice, and it produced a dose-related increase in thyroid neoplasms and compound-related nonneoplastic thyroid lesions in both sexes. The compound-related lesions are summarized below:

	MALES			FEMALES		
	Con- trol	Low Dose	High Dose	Con- trol	Low Dose	High Dose
<u>LIVER</u>						
(Number of animals with tissues examined histopathologically)	(39)	(45)	(43)	(46)	(49)	(46)
Hepatocellular Carcinoma	12	10	7	1	25	16
Hepatocellular Adenoma	0	3	6	0	3	11
<u>THYROID</u>						
(Number of animals with tissues examined histopathologically)	(38)	(46)	(43)	(44)	(49)	(45)
Follicular-Cell Adenoma (Papillary or Follicular-Cell Adenoma, Papillary Cystadenoma)	0	8	16	2	17	14
Follicular-Cell Carcinoma	0	1	1	2	0	1
Follicular-Cell Hyperplasia	2	12	9	2	1	4
C-Cell Adenoma	0	2	0	0	1	2
C-Cell Carcinoma	0	0	4	0	1	6

In male mice, dietary administration of the compound did not increase the incidence of hepatocellular neoplasms, whereas dosed females showed a striking increase in hepatocellular carcinomas and hepatocellular adenomas.

Grossly, hepatocellular neoplasms appeared as smooth, nodular, rounded masses distorting the normal shape of the liver. Color varied, many neoplasms appearing pale tan or dark red. Microscopically, hepatocellular carcinomas were expansive masses of hepatocytes exhibiting loss of normal architectural pattern, the cells being arranged in sheets or trabeculae instead of the normal lobules. Nuclei were frequently uniform, although variable amounts of pleomorphism did occur. The cytoplasm was either basophilic or acidophilic, sometimes varying from one region of the tumor to another, and was frequently pale. Lesions classified as hepatocellular adenomas were smaller, usually better differentiated, and were less pleomorphic than the hepatocellular carcinomas.

The criteria for classification of thyroid neoplasms in mice were the same as those used to classify thyroid neoplasms in rats. The nonneoplastic thyroid lesions found in dosed mice were similar to those in the rats but occurred in higher incidences. Hyperplasia of follicular cells (focal, papillary or adenomatous) were found in 2/38 (5 percent) control, 12/46 (26 percent) low dose, and 9/43 (21 percent) high dose male mice. Abundant golden brown pigment was seen in follicular epithelium, colloid, and macrophages. In the mice,

there were frequent foci of lymphocytes in the thyroid parenchyma and occasional cystic areas filled with amorphous material containing long clefts suggesting cholesterol crystals.

Three transitional-cell papillomas occurred in the bladder or urethra of dosed mice (two high dose males and one high dose female), but none occurred in controls.

Based upon the results of this pathologic examination, 1,5-naphthalenediamine was carcinogenic to B6C3F1 mice, producing hepatocellular neoplasms in females and thyroid neoplasms in both sexes.

#### D. Statistical Analyses of Results

The results of the statistical analyses of tumor incidence in mice are summarized in Tables 5 and 6. The analysis is included for every type of tumor in either sex where at least two such tumors were observed in at least one of the control or 1,5-naphthalenediamine-dosed groups and where such tumors were observed in at least 5 percent of the group.

For both male and female mice elevated incidences of thyroid tumors were observed in the dosed groups. In female mice the Cochran-Armitage test indicated a significant ( $P = 0.005$ ) positive association between dietary concentration and the incidence of C-cell carcinomas. This was supported by a significant ( $P = 0.014$ ) Fisher exact test for the high dose group. For males the Cochran-Armitage test result was also significant ( $P = 0.017$ ), but the Fisher exact tests were



TABLE 5  
ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT  
SPECIFIC SITES IN MALE MICE TREATED WITH 1,5-NAPHTHALENEDIAMINE<sup>a</sup>

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Lung: Alveolar/Bronchiolar Carcinoma <sup>b</sup>	2/39(0.05)	3/46(0.07)	0/45(0.00)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.272	0.000
Lower Limit	---	0.153	0.000
Upper Limit	---	14.686	4.478
Weeks to First Observed Tumor	109	82	---
<hr/>			
Lung: Alveolar/Bronchiolar Adenoma or Alveolar/Bronchiolar Carcinoma <sup>b</sup>	4/39(0.10)	9/46(0.20)	2/45(0.04)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Departure from Linear Trend <sup>e</sup>	P = 0.037	---	---
Relative Risk (Control) <sup>d</sup>	---	1.908	0.433
Lower Limit	---	0.582	0.041
Upper Limit	---	7.882	2.871
Weeks to First Observed Tumor	109	82	105
<hr/>			
Hematopoietic System: Malignant Lymphoma <sup>b</sup>	13/39(0.33)	14/47(0.30)	5/49(0.10)
P Values <sup>c</sup>	P = 0.007(N)	N.S.	P = 0.008(N)
Relative Risk (Control) <sup>d</sup>	---	0.894	0.306
Lower Limit	---	0.448	0.094
Upper Limit	---	1.817	0.829
Weeks to First Observed Tumor	100	82	95

TABLE 5 (CONTINUED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Liver: Hepatocellular Carcinoma <sup>b</sup>	12/39(0.31)	10/45(0.22)	7/43(0.16)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.722	0.529
Lower Limit	---	0.318	0.198
Upper Limit	---	1.620	1.306
Weeks to First Observed Tumor	86	88	105
Liver: Hepatocellular Carcinoma or Hepatocellular Adenoma <sup>b</sup>	12/39(0.31)	13/45(0.29)	13/43(0.30)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.939	0.983
Lower Limit	---	0.453	0.473
Upper Limit	---	1.981	2.071
Weeks to First Observed Tumor	86	88	105
Thyroid: C-Cell Carcinoma <sup>b</sup>	0/38(0.00)	0/46(0.00)	4/43(0.09)
P Values <sup>c</sup>	P = 0.017	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	---	Infinite
Lower Limit	---	---	0.825
Upper Limit	---	---	Infinite
Weeks to First Observed Tumor	---	---	105

TABLE 5 (CONCLUDED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Thyroid: C-Cell Carcinoma or C-Cell Adenoma <sup>b</sup>	0/38(0.00)	2/46(0.04)	4/43(0.09)
P Values <sup>c</sup>	P = 0.044	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	Infinite	Infinite
Lower Limit	---	0.246	0.825
Upper Limit	---	Infinite	Infinite
Weeks to First Observed Tumor	---	105	105
Thyroid: Papillary Adenoma, Follicular-Cell Adenoma, or Papillary Cystadenoma NOS <sup>b</sup>	0/38(0.00)	8/46(0.17)	16/43(0.37)
P Values <sup>c</sup>	P < 0.001	P = 0.006	P < 0.001
Relative Risk (Control) <sup>d</sup>	---	Infinite	Infinite
Lower Limit	---	1.905	4.523
Upper Limit	---	Infinite	Infinite
Weeks to First Observed Tumor	---	105	98

<sup>a</sup>Treated groups received doses of 0.1 or 0.2 percent in feed.

<sup>b</sup>Number of tumor-bearing animals/number of animals examined at site (proportion).

<sup>c</sup>The probability level for the Cochran-Armitage test is given beneath the incidence of tumors in the control group when  $P < 0.05$ ; otherwise, not significant (N.S.) is indicated. The probability level for the Fisher exact test for the comparison of a treated group with the control group is given beneath the incidence of tumors in the treated group when  $P < 0.05$ ; otherwise, not significant (N.S.) is indicated. For both Cochran-Armitage and Fisher exact tests a negative designation (N) indicates a lower incidence in the treated group(s) than in the control group.

<sup>e</sup>The probability level of the test for departure from linear trend is given beneath the control group when  $P < 0.05$ .

TABLE 6  
ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT  
SPECIFIC SITES IN FEMALE MICE TREATED WITH 1,5-NAPHTHALENEDIAMINE<sup>a</sup>

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Lung: Alveolar/Bronchiolar Carcinoma <sup>b</sup>	0/49(0.00)	1/48(0.02)	3/46(0.07)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	Infinite	Infinite
Lower Limit	---	0.055	0.638
Upper Limit	---	Infinite	Infinite
Weeks to First Observed Tumor	---	89	91
48 Lung: Alveolar/Bronchiolar Adenoma or Alveolar/Bronchiolar Carcinoma <sup>b</sup>	0/49(0.00)	10/48(0.21)	5/46(0.11)
P Values <sup>c</sup>	N.S.	P = 0.001	P = 0.024
Departure from Linear Trend <sup>e</sup>	P = 0.005	---	---
Relative Risk (Control) <sup>d</sup>	---	Infinite	Infinite
Lower Limit	---	3.037	1.347
Upper Limit	---	Infinite	Infinite
Weeks to First Observed Tumor	---	89	91
Hematopoietic System: Leukemia or Malignant Lymphoma <sup>b</sup>	13/49(0.27)	19/50(0.38)	5/46(0.11)
P Values <sup>c</sup>	N.S.	N.S.	P = 0.045(N)
Departure from Linear Trend <sup>e</sup>	P = 0.011	---	---
Relative Risk (Control) <sup>d</sup>	---	1.432	0.410
Lower Limit	---	0.760	0.124
Upper Limit	---	2.781	1.117
Weeks to First Observed Tumor	57	63	105

TABLE 6 (CONTINUED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Liver: Hepatocellular Carcinoma <sup>b</sup>	1/46(0.02)	25/49(0.51)	16/46(0.35)
P Values <sup>c</sup>	P = 0.001	P < 0.001	P < 0.001
Departure from Linear Trend <sup>e</sup>	P < 0.001	---	---
Relative Risk (Control) <sup>d</sup>	---	23.469	16.000
Lower Limit	---	4.156	2.683
Upper Limit	---	906.346	646.516
Weeks to First Observed Tumor	109	74	99
Liver: Hepatocellular Adenoma or Hepatocellular Carcinoma <sup>b</sup>	1/46(0.02)	28/49(0.57)	27/46(0.59)
P Values <sup>c</sup>	P < 0.001	P < 0.001	P < 0.001
Departure from Linear Trend <sup>e</sup>	P = 0.002	---	---
Relative Risk (Control) <sup>d</sup>	---	26.286	27.000
Lower Limit	---	4.741	4.874
Upper Limit	---	1030.801	1027.943
Weeks to First Observed Tumor	109	74	99
Stomach: Squamous-Cell Papilloma <sup>b</sup>	0/41(0.00)	3/47(0.06)	0/46(0.00)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Departure from Linear Trend <sup>e</sup>	P = 0.017	---	---
Relative Risk (Control) <sup>d</sup>	---	Infinite	---
Lower Limit	---	0.529	---
Upper Limit	---	Infinite	---
Weeks to First Observed Tumor	---	105	---

TABLE 6 (CONTINUED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Pituitary: Adenoma NOS, Chromophobe Adenoma or Acidophil Adenoma <sup>b</sup>	3/34(0.09)	4/35(0.11)	1/30(0.03)
P Values <sup>c</sup>	N.S.	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	1.295	0.378
Lower Limit	---	0.238	0.007
Upper Limit	---	8.188	4.424
Weeks to First Observed Tumor	109	105	106
Adrenal: Pheochromocytoma <sup>b</sup>	3/46(0.07)	0/44(0.00)	0/44(0.00)
P Values <sup>c</sup>	P = 0.040(N)	N.S.	N.S.
Relative Risk (Control) <sup>d</sup>	---	0.000	0.000
Lower Limit	---	0.000	0.000
Upper Limit	---	1.731	1.731
Weeks to First Observed Tumor	68	---	---
Thyroid: C-Cell Carcinoma <sup>b</sup>	0/44(0.00)	1/49(0.02)	6/45(0.13)
P Values <sup>c</sup>	P = 0.005	N.S.	P = 0.014
Relative Risk (Control) <sup>d</sup>	---	Infinite	Infinite
Lower Limit	---	0.048	1.574
Upper Limit	---	Infinite	Infinite
Weeks to First Observed Tumor	---	105	105

TABLE 6 (CONCLUDED)

TOPOGRAPHY:MORPHOLOGY	CONTROL	LOW DOSE	HIGH DOSE
Thyroid: C-Cell Adenoma or C-Cell Carcinoma <sup>b</sup>	0/44(0.00)	2/49(0.04)	8/45(0.18)
P Values <sup>c</sup>	P = 0.001	N.S.	P = 0.003
Relative Risk (Control) <sup>d</sup>	---	Infinite	Infinite
Lower Limit	---	0.267	2.250
Upper Limit	---	Infinite	Infinite
Weeks to First Observed Tumor	---	105	41
Thyroid: Papillary Adenoma, Follicular-Cell Adenoma, or Papillary Cystadenoma NOS <sup>b</sup>	2/44(0.05)	17/49(0.35)	14/45(0.31)
P Values <sup>c</sup>	P = 0.003	P < 0.001	P = 0.001
Departure from Linear Trend <sup>e</sup>	P = 0.025	---	---
Relative Risk (Control) <sup>d</sup>	---	7.633	6.844
Lower Limit	---	1.971	1.709
Upper Limit	---	64.662	58.827
Weeks to First Observed Tumor	80	105	91

<sup>a</sup>Treated groups received doses of 0.1 or 0.2 percent in feed.

<sup>b</sup>Number of tumor-bearing animals/number of animals examined at site (proportion).

<sup>c</sup>The probability level for the Cochran-Armitage test is given beneath the incidence of tumors in the control group when  $P < 0.05$ ; otherwise, not significant (N.S.) is indicated. The probability level for the Fisher exact test for the comparison of a treated group with the control group is given beneath the incidence of tumors in the treated group when  $P < 0.05$ ; otherwise, not significant (N.S.) is indicated. For both Cochran-Armitage and Fisher exact tests a negative designation (N) indicates a lower incidence in the treated group(s) than in the control group.

<sup>d</sup>The 95% confidence interval on the relative risk of the treated group to the control group.

<sup>e</sup>The probability level of the test for departure from linear trend is given beneath the control group when  $P < 0.05$ .

not. When incidences were combined so that the numerator represented mice with either a papillary adenoma, a follicular-cell adenoma, or a papillary cystadenoma of the thyroid, the Cochran-Armitage test indicated a significant positive association between dietary concentration and tumor incidence for both males ( $P < 0.001$ ) and females ( $P = 0.003$ ). These were supported by significant ( $P \leq 0.006$ ) Fisher exact test results in each sex for comparisons of each dosed group to the control group. Based on these results, the administration of 1,5-naphthalenediamine was associated with the incidence of thyroid neoplasms in both male and female mice.

For females an increased incidence of hepatocellular carcinomas was also observed among the dosed mice. The Cochran-Armitage test indicated a significant ( $P = 0.001$ ) positive association between dose and incidence. This was supported by significant ( $P < 0.001$ ) comparisons of both the high and low dose to the control group using the Fisher exact test. Based on these results the administration of 1,5-naphthalenediamine was associated with the incidence of hepatocellular carcinomas in female mice.

For female mice, when the incidence of alveolar/bronchiolar adenomas and alveolar/bronchiolar carcinomas were combined, an increased incidence in the dosed groups was noted. The Fisher exact test was significant for both the high ( $P = 0.024$ ) and low ( $P = 0.001$ ) dose groups. The departure from linear trend was significant since tumor incidence was increased more in the low dose than in the high



dose group. In historical control data compiled by this laboratory for the NCI Carcinogenesis Testing Program, 17/275 (6 percent) of the untreated female B6C3F1 mice had an alveolar/bronchiolar neoplasm. Based upon these results the administration of 1,5-naphthalenediamine was associated with the incidence of alveolar/bronchiolar neoplasms in female mice.

For females the Fisher exact test comparing the incidence of leukemia or malignant lymphoma in high dose mice with that in the controls had a probability level in the negative direction of  $P = 0.045$ , a marginal result which was not significant under the Bonferroni criterion.

Also for females the Cochran-Armitage test showed a significant ( $P = 0.040$ ) negative association between dose and the incidence of adrenal pheochromocytomas, but the Fisher exact tests were not significant.

In male mice the possibility of a negative association between dose and the incidence of malignant lymphomas or leukemia was noted.

Based upon these statistical results the administration of 1,5-naphthalenediamine was associated with the increased incidence of thyroid neoplasms in male mice and of thyroid neoplasms, of hepatocellular carcinomas, and of alveolar/bronchiolar neoplasms in female mice.

## V. DISCUSSION

There were no significant positive associations between dietary concentrations of 1,5-naphthalenediamine and mortality in either sex of rats or mice. In all groups adequate numbers of animals survived sufficiently long to be at risk from late-developing tumors.

Several uterine neoplasms occurred in dosed female rats at higher incidences than in corresponding controls. There was a significant positive association between dietary concentration of the compound and the incidences of endometrial stromal polyps in female rats. In addition, the high dose to control Fisher exact comparison was significant. Endometrial stromal sarcomas were observed in two low dose and two high dose female rats, but not in controls. Uterine adenocarcinomas occurred at a higher incidence in the high dose female rat group than in the control group, but the difference in tumor incidence was not statistically significant.

The administration of 1,5-naphthalenediamine was associated with an elevated incidence of clitoral gland neoplasms in female rats. There was a significant positive association between the concentration of the chemical added to the diet and the incidence of either adenomas or carcinomas of the clitoral gland in female rats. The incidence of either of these neoplasms in the high dose female rat group was significant relative to the incidence in the control group.

Elevated incidences of thyroid neoplasms were observed among dosed mice. For mice of both sexes there were significant positive

associations between dietary concentration of 1,5-naphthalenediamine and the incidences of thyroid C-cell carcinomas. For the females the high dose to control Fisher exact comparison supported the finding; this was not true for males. When the mice were grouped so that the numerator of the incidence represented those animals with a papillary adenoma, a follicular-cell adenoma, or a papillary cystadenoma of the thyroid, the Cochran-Armitage test was significantly positive for both males and females and all the Fisher exact comparisons supported the findings.

The incidence of hepatocellular carcinomas in female mice was significantly associated with increased concentration of 1,5-naphthalenediamine. In addition, the high dose to control and the low dose to control Fisher exact comparisons were significant. The incidence of alveolar/bronchiolar adenomas was significant, relative to controls, in both the low dose and the high dose female mouse groups.

Under the conditions of this bioassay, 1,5-naphthalenediamine was carcinogenic in female Fischer 344 rats, causing clitoral and uterine neoplasms. 1,5-Naphthalenediamine was also carcinogenic for B6C3F1 mice, producing thyroid neoplasms in males and neoplasms of the thyroid, liver, and lung in females. Insufficient evidence was provided for the carcinogenicity of the compound in male Fischer 344 rats.

## VI. BIBLIOGRAPHY

- Anthony, H.M., and G.M. Thomas, "Tumors of the Urinary Bladder: An Analysis of the Occupations of 1,030 Patients in Leeds, England." Journal of the National Cancer Institute 45:879-895, 1970.
- Armitage, P., Statistical Methods in Medical Research, Chapter 14. J. Wiley & Sons, New York, 1971.
- Berenblum, I., editor, Carcinogenicity Testing. International Union Against Cancer, Technical Report Series, Vol. 2. International Union Against Cancer, Geneva, 1969.
- Chemical Abstracts Service, The Chemical Abstracts Service (CAS) Ninth Collective Index, Volumes 76-85, 1972-1976. American Chemical Society, Washington, D.C., 1977.
- Cox, D.R., Analysis of Binary Data, Chapters 4 and 5. Methuen and Co., Ltd., London, 1970.
- Cox, D.R., "Regression Models and Life-Tables." Journal of the Royal Statistical Society, Series "B" 34:187-220, 1972.
- Freeman, H.G., G.F. Baxter, and G.T. Tiedeman, "Rapid Curing Resin Compositions Comprising a Phenol-Aldehyde Condensation Polymer Modified with an Aminonaphthalene." U.S. Patent 3,786,025 (Weyerhaeuser Co.) January 15, 1974; Chemical Abstracts 81, 78678u.
- Fujiwara, T., K. Nagosawa, T. Tsumaki, S. Goto, and S. Fukuoka, "Piperazine-Modified Aromatic Polyamide Fibers." Japan Kokai 74,116,322 (Asahi Chemical Industry Co., Ltd.) November 7, 1974; Chemical Abstracts 83, 12023m.
- Gart, J.J., "The Comparison of Proportions: A Review of Significance Tests, Confidence Limits, and Adjustments for Stratification." International Statistical Institute Review 39:148-169, 1971.
- Hall, C.M., "Pharmaceutical Compositions Containing 1,4,7,10-Tetrahydro-1,7-dioxoquino-8,7-h quinoline-3,9-dicarboxylic Acid Derivatives or Salts." U.S. Patent 3,953,598 (Upjohn Co.) April 27, 1976; Chemical Abstracts 85, 372484.
- Hirai, Y., and R. Yamamoto, "Purification of 1,5-Naphthalenediisocyanate." Japan. Kokai 75 12,062 (Mitsui Toatsu Chemicals, Inc.) February 7, 1975; Chemical Abstracts 82, 155968p.

- International Agency for Research on Cancer, IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man: Some Aromatic Amines, Hydrazine and Related Substances, N-Nitroso Compounds, and Miscellaneous Alkylating Agents, Volume 4. IARC, Lyon, France, 1974.
- Kaplan, E.L., and P. Meier, "Nonparametric Estimation from Incomplete Observations." Journal of the American Statistical Association 53:457-481, 1958.
- Linhart, M.S., J.A. Cooper, R.L. Martin, N.P. Page, and J.A. Peters, "Carcinogenesis Bioassay Data System." Computers and Biomedical Research 7:230-248, 1974.
- Miller, R.G., Simultaneous Statistical Inference. McGraw-Hill Book Co., New York, 1966.
- Pollock, J.R.A. and R. Stevens, editors, Dictionary of Organic Compounds, 4th edition, Volume 4. Oxford University Press, New York, 1965.
- Sadtler Standard Spectra. Sadtler Research Laboratories, Philadelphia, Pennsylvania. UV No. 7846.
- Saffiotti, U., R. Montesano, A.R. Sellakumar, F. Cefis, and D.G. Kaufman, "Respiratory Tract Carcinogenesis in Hamsters Induced by Different Numbers of Administration of Benzo (a) Pyrene and Ferric Oxide." Cancer Research 32:1073-1079, 1972.
- Society of Dyers and Colourists. Colour Index, 2nd edition, Volume 3. Yorkshire, England, 1956.
- Stanford Research Institute, 1977 Directory of Chemical Producers, U.S.A. Menlo Park, California, 1977.
- Tarone, R.E., "Tests for Trend in Life-Table Analysis." Biometrika 62:679-682, 1975.
- Taube, C., "Trisazo Dye." Ger. Offen. 2,211,638 (Bayer A.-G.) September 20, 1973; Chemical Abstracts 80, 4901u.
- Wynder, E.L., J. Onderdonk, and N. Mantel, "An Epidemiological Investigation of Cancer of the Blader." Cancer 16:1388-1407, 1963.

Review of the Bioassay of 1,5-Naphthalenediamine\*  
for Carcinogenicity

by the Data Evaluation/Risk Assessment Subgroup  
of the Clearinghouse on Environmental Carcinogens

June 29, 1978

The Clearinghouse on Environmental Carcinogens was established in May, 1976, in compliance with DHEW Committee Regulations and the Provisions of the Federal Advisory Committee Act. The purpose of the Clearinghouse is to advise the Director of the National Cancer Institute (NCI) on its bioassay program to identify and to evaluate chemical carcinogens in the environment to which humans may be exposed. The members of the Clearinghouse have been drawn from academia, industry, organized labor, public interest groups, State health officials, and quasi-public health and research organizations. Members have been selected on the basis of their experience in carcinogenesis or related fields and, collectively, provide expertise in chemistry, biochemistry, biostatistics, toxicology, pathology, and epidemiology. Representatives of various Governmental agencies participate as ad hoc members. The Data Evaluation/Risk Assessment Subgroup of the Clearinghouse is charged with the responsibility of providing a peer review of reports prepared on NCI-sponsored bioassays of chemicals studied for carcinogenicity. It is in this context that the below critique is given on the bioassay of 1,5-Naphthalenediamine for carcinogenicity.

The reviewer agreed with the conclusion in the report that 1,5-Naphthalenediamine was carcinogenic in treated female rats and in both sexes of mice. He noted that the study was conducted in a room in which other compounds were under test. Based on the experimental findings, he concluded that 1,5-Naphthalenediamine may pose a carcinogenic risk to humans. The reviewer moved that the report on the bioassay of 1,5-Naphthalenediamine be accepted as written. The motion was approved without objection.

Clearinghouse Members present:

Arnold L. Brown (Chairman), Mayo Clinic  
Paul Nettesheim, National Institute of Environmental  
Health Sciences  
Verne Ray, Pfizer Medical Research Laboratory  
Verald K. Rowe, Dow Chemical U.S.A.  
Michael B. Shimkin, University of California at San Diego  
Louise Strong, University of Texas Health Sciences Center

\* Subsequent to this review, changes may have been made in the bioassay report either as a result of the review or other reasons. Thus, certain comments and criticisms reflected in the review may no longer be appropriate.



## 1. Chemical and Physical Data


### 1.1 Synonyms and trade names

*Chem. Abstr. Services Reg. No.:* 2243-62-1

*Chem. Abstr. Name and IUPAC Systematic Name:* 1,5-Naphthalenediamine

*Synonyms:* 1,5-Diaminonaphthalene; 1,5-naphthylenediamine

### 1.2 Structural and molecular formulae and molecular weight



$C_{10}H_{10}N_2$

Mol. wt: 158.2

### 1.3 Chemical and physical properties of the pure substance

From Weast (1979), unless otherwise specified

(a) *Description:* Colourless crystals (Hawley, 1977)

(b) *Boiling-point:* Sublimes

(c) *Melting-point:* 190°

(d) *Density:* 1.4

(e) *Solubility:* Soluble in hot water, ethanol and diethyl ether; very soluble in chloroform, hot ethanol and hot diethyl ether

(f) *Spectroscopic data:* Infra-red and ultra-violet spectral data have been reported (Sadtler Research Laboratories, Inc., undated).

### 1.4 Technical products and impurities

No data were available to the Working Group.

## 2. Production, Use, Occurrence and Analysis

### 2.1 Production and use

#### (a) Production

1,5-Naphthalenediamine can be prepared by the reduction of 1,5-dinitronaphthalene (Sandridge & Staley, 1978) or by ammonolysis of 1,5-dihydroxynaphthalene. Both methods are believed to be used for its commercial production in Japan.

1,5-Naphthalenediamine is believed to be produced by two companies in the Federal Republic of Germany. It has been produced commercially in Japan since 1957; in 1979, two companies produced an estimated 50 thousand kg.

No evidence was found that 1,5-naphthalenediamine has ever been produced in commercial quantities in the US. Two thousand kg were imported through principal US customs districts in 1979 (US International Trade Commission, 1980).

#### (b) Use

1,5-Naphthalenediamine is believed to be used almost exclusively as an intermediate for the manufacture of 1,5-naphthalene diisocyanate and organic dyes. In Japan, an estimated 75% is consumed in the production of the isocyanate and 25% in dye synthesis.

1,5-Naphthalene diisocyanate, the subject of an earlier monograph (IARC, 1979), is used in Japan and western Europe in the production of polyurethane elastomers. The Society of Dyers & Colourists (1971) reports that 1,5-naphthalenediamine can serve as an oxidation base and that one dye can be prepared from it. No evidence was found that it is presently used commercially in these two applications. The nature of the dyes presently being produced in commercial quantities from 1,5-naphthalenediamine is not known.

### 2.2 Occurrence

1,5-Naphthalenediamine has not been reported to occur as a natural product. No data on its occurrence in the environment were available to the Working Group.

### 2.3 Analysis

An IARC manual (Egan *et al.*, 1981) gives selected methods for the analysis of aromatic amines. No information on quantitative methods of analysis for 1,5-naphthalenediamine were available to the Working Group.



### 3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

#### 3.1 Carcinogenicity studies in animals

##### *Oral administration*

*Mouse:* Groups of 50 male and 50 female B6C3F<sub>1</sub> mice, approximately seven weeks of age, were fed diets containing 1000 or 2000 mg/kg 1,5-naphthalenediamine (probably no more than 89% pure, with at least one unspecified impurity detected by thin-layer chromatography) for 103 weeks. The doses were selected on the basis of a range-finding study [see section 3.2(a)]. Groups of 50 mice of each sex served as matched controls. All animals in the study received food and water *ad libitum* and all were treated for parasites with 3 g/L piperazine adipate added for three days per week to the drinking-water for two weeks prior to treatment with the test chemical. The observation periods were 105-106 weeks for treated mice and 109 weeks for controls. There was no significant association between dose of 1,5-naphthalenediamine and mortality in animals of either sex; 58-82% of treated mice and 60-66% of controls survived the observation period. Statistically significant increases in tumour incidence were observed for the following neoplasms: (a) a dose-related increase ( $P = 0.005$ ) in C-cell carcinomas of the thyroid gland in females: controls, 0/44; low-dose, 1/49; high-dose, 6/45 ( $P = 0.014$ ); (b) dose-related increases ( $P < 0.001$  and  $P = 0.003$ ) in neoplasms of the thyroid gland (follicular-cell adenomas, papillary adenomas and papillary adenomas plus papillary cystadenomas) in 0/38 male controls, 8/46 low-dose males ( $P = 0.006$ ), 16/43 high-dose males ( $P < 0.001$ ), 2/44 female controls, 17/49 low-dose females ( $P < 0.001$ ) and 14/45 high-dose females ( $P = 0.001$ ); (c) an increase in hepatocellular carcinomas in females: controls, 1/46; low-dose, 25/49 ( $P < 0.001$ ); high-dose, 16/46 ( $P < 0.001$ ); and (d) an increase in alveolar/bronchiolar adenomas and carcinomas in females: controls, 0/49; low-dose, 10/48 ( $P = 0.001$ ); high-dose, 5/46 ( $P = 0.024$ ) (National Cancer Institute, 1978).

*Rat:* Groups of 50 male and 50 female Fischer 344 rats, approximately seven weeks of age, were fed diets containing 500 or 1000 mg/kg 1,5-naphthalenediamine (same sample as used above) for 103 weeks. The doses were selected on the basis of a range-finding study [see section 3.2(a)]. Groups of 25 rats of each sex served as matched controls. All animals under study received food and water *ad libitum*, and all were treated for parasites with piperazine adipate added for three days to the drinking-water (followed by three days of plain tap-water and three subsequent days of piperazine adipate) two weeks prior to treatment with the test chemical. The observation periods were 106-107 weeks for treated rats and 109-110 weeks for controls. There was no significant association between dose of 1,5-naphthalenediamine and mortality of animals of either sex: 74-80% of treated rats and 64-68% of controls survived the observation period. A statistically significant, dose-related increase ( $P = 0.003$ ) in the incidence of adenomas plus carcinomas of the clitoral gland was observed: controls, 1/24; low-dose, 3/50; high-dose, 13/50 ( $P = 0.021$ ) (National Cancer Institute, 1978). [The Working Group noted that the increase in the incidence of clitoral gland tumours was only marginally significant, and that histological section of this organ was performed only when it showed gross abnormality.]

### 3.2 Other relevant biological data

#### *(a) Experimental systems*

##### *Toxic effects*

No LD<sub>50</sub> values were available to the Working Group.

In eight-week subchronic feeding studies, male and female Fischer 344 rats and B6C3F<sub>1</sub> mice received up to 3.0% 1,5-naphthalenediamine in the diet. Some deaths were observed in treated groups fed 0.3% or more. Mean body weight gain was depressed by 3-22%. No compound-related lesions were observed in chronic studies with 1,5-naphthalenediamine in rats and mice (highest dose, 0.1% in rats and 0.2% in mice) (National Cancer Institute, 1978).

##### *Effects on reproduction and prenatal toxicity*

No data were available to the Working Group.

##### *Absorption, distribution, excretion and metabolism*

No data were available to the Working Group.

##### *Mutagenicity and other short-term tests*

1,5-Naphthalenediamine (same sample as used in the carcinogenicity tests) was mutagenic to *Salmonella typhimurium* strain TA100 without metabolic activation (Dunkel & Simmon, 1980).

#### *(b) Humans*

No data were available to the Working Group.

### 3.3 Case reports and epidemiological studies of carcinogenicity in humans

No data were available to the Working Group.